Anixa Biosciences presented final data from the Phase 1 clinical trial of its investigational breast cancer vaccine.
Results showed the vaccine met all major primary endpoints and was well tolerated at the maximum tolerated dose.
The combination of Keytruda and the vaccine generated T cell responses with no major additional side effects.
Phase 1 Findings
Investigational vaccine met primary endpoints, safe, and generated immune responses in 74% of participants.
Vaccine Safety
Well tolerated at the maximum tolerated dose with primarily injection-site irritation as adverse events.
Phase 2 Development
Results support the advancement of the program into Phase 2 development.
Combination Study
Plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patients.
- Final Phase 1 results showcased the safety and efficacy of the investigational breast cancer vaccine.
- The positive immune responses in participants indicate a promising advancement in cancer treatment.
The successful Phase 1 trial results pave the way for further evaluation and potential advancements in breast cancer treatment. Anixa Biosciences is making significant strides in the fight against cancer.